SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-056466
Filing Date
2021-11-12
Accepted
2021-11-12 07:32:01
Documents
70
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tals-10q_20210930.htm   iXBRL 10-Q 3300716
2 EX-31.1 tals-ex311_9.htm EX-31.1 20765
3 EX-31.2 tals-ex312_8.htm EX-31.2 20790
4 EX-32.1 tals-ex321_6.htm EX-32.1 9603
5 EX-32.2 tals-ex322_7.htm EX-32.2 9741
  Complete submission text file 0001564590-21-056466.txt   9464035

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tals-20210930.xsd EX-101.SCH 50164
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tals-20210930_cal.xml EX-101.CAL 38286
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tals-20210930_def.xml EX-101.DEF 215066
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20210930_lab.xml EX-101.LAB 416543
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20210930_pre.xml EX-101.PRE 336772
11 EXTRACTED XBRL INSTANCE DOCUMENT tals-10q_20210930_htm.xml XML 1544996
Mailing Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202
Business Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202 502-569-1059
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40384 | Film No.: 211399595
SIC: 2836 Biological Products, (No Diagnostic Substances)